Project Grant R43CA250939

This Project Grant award of $306,798 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop an artificial intelligence-based system to accurately identify malignant lymph nodes. The key objectives are to: Create a lymph node segmentation model to enable extraction of radiomic features critical for malignancy classification. Develop both cloud-based and standalone desktop deployment options for the classification model to...

This $1,107,943 Project Grant from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) was awarded to Illuminant Surgical Inc. to continue development and validation of the Skylight mixed-reality navigation platform for image-guided cancer biopsies. The key objectives of this Phase II effort are to: (1) develop and test software algorithms for tracking and compensating respiratory motion, (2) create a cadaveric model with physiologic respiratory movement for...

Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop a digital pathology "laboratory-in-a-box" solution that produces and analyzes high-resolution, 3D digital pathology images at the point of care within seconds. The solution combines rapid confocal imaging hardware with AI-enabled software to automatically recolorize and interpret the digital...

This Project Grant award of $2,223,201.00, funded by the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health), supports the development of an Augmented Reality (AR) guidance system with deformation modeling to aid in the relocation of tumor margins during head and neck cancer surgery. The project, conducted by Vanderbilt University, aims to improve the success rate of re-resection...

The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...

This federal Project Grant award, valued at $306,872 and provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to develop a new imaging system termed the Multi-Camera Array Scanner (MCAS). The MCAS will enable rapid 3D digitization and automated analysis of thick fine-needle aspiration (FNA) cytology smears, which are a critical first step in the cancer diagnosis pipeline. The project is a collaboration between Ramona Optics Inc., a small...

The U.S. National Cancer Institute (NCI) awarded a $1,073,736 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Rivanna Medical, Inc. to develop an AI-assisted, ultrasound-based interventional guidance platform to reduce traumatic lumbar puncture (LP) rates in pediatric oncology patients. The key innovations for this medical device include imaging algorithms that highlight anatomical landmarks, automated injection site selection, a novel dual-array...

The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $225,229 Project Grant to Navigation Sciences Inc. on September 19, 2025. The grant will fund the development of a novel navigation software system, EndonaviSCI, to address key challenges in lung cancer surgery. The EndonaviSCI system aims to: 1) Ensure accurate localization and placement of a wireless electromagnetic sensor (J-bar) next to the tumor without the need for...

The federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research Program (CFDA 93.394) provided $1,164,814 to O2M Technologies LLC to develop an advanced imaging system using pulse electron paramagnetic resonance (PEPR) techniques. The goal is to create a fast and precise method for measuring partial oxygen pressure (pO2) in tissues, which can guide cancer treatment and other medical applications. The project involves establishing the hardware for...